No­vo Nordisk scores a win for semaglu­tide in obe­si­ty, po­ten­tial­ly set­ting up a next-gen bat­tle with Eli Lil­ly

No­vo Nordisk pulled a high­ly an­tic­i­pat­ed win for its GLP-1 ther­a­py semaglu­tide in obe­si­ty on Fri­day, be­com­ing the first com­pa­ny to get a chron­ic weight man­age­ment drug for adults past reg­u­la­tors since 2014.

Semaglu­tide — mar­ket­ed for type 2 di­a­betes as Ozem­pic — was first ap­proved in 2017. The block­buster gen­er­at­ed $3.4 bil­lion in sales last year, sur­pass­ing No­vo’s old­er GLP-1 drug Vic­toza. It’ll be mar­ket­ed as We­govy in obe­si­ty, and No­vo ex­pects to start rolling it out lat­er this month.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.